What are the benefits of working at CyberAgent?
CyberAgent, a prominent digital media and internet enterprise, offers an exceptional employee benefits ecosystem designed to attract top-tier engineering and creative talent. Working at the company provides opportunities to engage in high-impact digital projects, cutting-edge artificial intelligence research, and innovative media platforms with global reach. CyberAgent fosters a dynamic, meritocratic corporate culture that encourages professional autonomy, rapid career advancement, and continuous skill development. Employees typically enjoy competitive compensation structures, performance-based bonuses, comprehensive health and wellness support programs, and flexible work arrangements that promote a balanced, collaborative, and highly stimulating professional environment.
Related FAQs
CyberAgent, Inc. is a major Japanese digital media, advertising, and internet enterprise headquartered in Tokyo.
CyberAgent's mission is "to break through stagnation with new power and the internet," focusing on overcoming stagnation via digital innovation, contributing to the digital transformation of industries, and competing globally by fusing technology wit...
CyberAgent, Inc. is a prominent Japanese digital enterprise operating major business segments spanning media streaming, internet advertising, and mobile video game development.
CyberAgent's market capitalization as of August 2026 is approximately $4.66 billion USD.
CyberAgent, a prominent Japanese technology and media firm, generally receives positive marks from employees regarding its company culture and work-life balance.
CyberAgent's annual revenue for the fiscal year ending September 30, 2025, was 874.03 billion JPY, marking a 9.09% year-over-year growth.
CyberAgent’s culture emphasizes innovation, "freedom with self-responsibility," talent development, and teamwork.
CyberAgent, Inc. is a prominent Japanese digital enterprise operating diverse subsidiaries across internet media, video streaming, and online gaming sectors.
CyberAgent maintains a clear commitment to ethical research and corporate responsibility, aiming to use technology for the advancement of society.
Cytokinetics, Incorporated is a prominent, publicly traded biopharmaceutical enterprise headquartered in South San Francisco, California, focusing on the discovery and development of muscle activators and novel treatments for cardiovascular and neuro...
As of August 2026, CyberAgent has a market capitalization of approximately $4.66 billion USD.
Yes, Cytokinetics has received FDA approval for its drug MYQORZO (aficamten). The drug was approved in late 2025 for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms.
CyberAgent reported revenue of 874.03 billion JPY for the fiscal year ending September 30, 2025.
Yes, CyberAgent is heavily involved in artificial intelligence research and development.